Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
To switch (statins) or not to switch? That is the question..
Expert Opin Pharmacother. 11(18), 2943-6.
(2010). Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?.
Curr Vasc Pharmacol. 8(5), 720-30.
(2010). Adrenal incidentaloma: a diagnostic challenge..
Hormones (Athens). 8(3), 163-84.
(2009). Anti-inflammatory effects of fibrates: an overview..
Curr Med Chem. 16(6), 676-84.
(2009). Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?.
Angiology. 60(4), 397-402.
(2009). Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?.
Angiology. 60(1), 74-81.
(2009). Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis..
J Clin Endocrinol Metab. 94(8), 2692-701.
(2009). Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus..
Nat Clin Pract Endocrinol Metab. 5(1), 16-7.
(2009). A comparison of the aldosterone-blocking agents eplerenone and spironolactone..
Clin Cardiol. 32(4), 230.
(2009). Dyslipidemia as a risk factor for ischemic stroke..
Curr Top Med Chem. 9(14), 1291-7.
(2009). Implementation of guidelines for the management of arterial hypertension. The impulsion study..
Open Cardiovasc Med J. 3, 26-34.
(2009). JUPITER: major implications for vascular risk assessment..
Curr Med Res Opin. 25(1), 133-7.
(2009). The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?.
Hellenic J Cardiol. 50(2), 89-91.
(2009). Lipoprotein a: where are we now?.
Curr Opin Cardiol. 24(4), 351-7.
(2009). Multifactorial intervention for the prevention of vascular complications of type 2 diabetes..
Hellenic J Cardiol. 50(6), 445-8.
(2009). Pleiotropic effects of statins--clinical evidence..
Curr Pharm Des. 15(5), 479-89.
(2009). The role of statins for the primary and secondary prevention of coronary heart disease in women..
Curr Pharm Des. 15(10), 1054-62.
(2009). Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention..
Curr Vasc Pharmacol. 7(3), 264-6.
(2009). Triglycerides and vascular risk: insights from epidemiological data and interventional studies..
Curr Drug Targets. 10(4), 320-7.
(2009). Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?.
Expert Opin Investig Drugs. 17(7), 969-72.
(2008). Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?.
Expert Opin Investig Drugs. 17(4), 445-9.
(2008). CORONA, statins, and heart failure: who lost the crown?.
Angiology. 59(1), 5-8.
(2008). Do we need to consider inflammatory markers when we treat atherosclerotic disease?.
Atherosclerosis. 200(1), 1-12.
(2008).
(2008).
(2008).